Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$8.32 - $13.21 $46,841 - $74,372
5,630 New
5,630 $49,000
Q1 2022

Apr 29, 2022

SELL
$14.08 - $27.63 $20,345 - $39,925
-1,445 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$26.55 - $40.57 $38,364 - $58,623
1,445 New
1,445 $38,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track C M Bidwell & Associates LTD Portfolio

Follow C M Bidwell & Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on C M Bidwell & Associates LTD with notifications on news.